SYNTEX' TRI-NORINYL PATENT EXPIRES IN 2000, FDA APPROVED Rx DRUG LIST NOTES
Syntex' Tri-Norinyl patent will expire on June 28, 2000, according to information contained in the most recent (August 1984-November 1984) supplement to FDA's "Approved Rx Drug Products List." The supplement to the Rx listing is the first to contain the patent information mandated by the Hatch/Waxman patent legislation. The list now contains patent "numbers and expiration dates; and for drug products approved after 1982, the date of approval and application number as required" by the new law, a preface to the document explains. The agency added that it intends to publish additional information on exclusivity in the next supplement. The list includes, but does not distinguish between, both ingredient patents and use patents for a particular indication or method of using the product. As a result, severan patent expiration dates are listed (for sample page, see box below). The Syntex low-dose oral contraceptive is one of a handful of products on the initial list, which, according to FDA, have patent protection extending into the next century. Others in the group are Travenol labs' Branchamin (injectible amino acids), and Mylan's Maxzide (oral triamterene/hydrochlorothiazide), both with patents extending to 2001. FDA noted in the supplement that it "invites comments from all interested parties on whether it has excluded any patents that should have been included or included patents that should have been excluded." Chart omitted.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth